- Home
- STAA vs ANL Comparison
STAA vs ANL Comparison
Compare STAA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STAA | ANL |
|---|---|---|
| Founded | 1982 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.9M | 703.3M |
| IPO Year | 1995 | 2022 |
Fundamental Metrics
Financial Performance| Metric | STAA | ANL |
|---|---|---|
| Price | $25.63 | $16.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $22.81 | $20.00 |
| AVG Volume (30 Days) | ★ 1.3M | 551.4K |
| Earning Date | 05-06-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $239,442,000.00 | N/A |
| Revenue This Year | $28.87 | $36.02 |
| Revenue Next Year | $7.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.59 | $0.88 |
| 52 Week High | $30.81 | $16.97 |
Technical Indicators
Market Signals| Indicator | STAA | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 68.90 | 74.22 |
| Support Level | $23.79 | $1.36 |
| Resistance Level | $27.52 | N/A |
| Average True Range (ATR) | 1.18 | 2.40 |
| MACD | 0.38 | 0.75 |
| Stochastic Oscillator | 84.91 | 97.83 |
Price Performance
Historical ComparisonAbout STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.